Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Company Update - Avadel Pharmaceuticals plc will host a conference call and live webcast on May 8, 2024, at 8:30 a.m. ET to provide a corporate update and discuss financial results for Q1 2024 [1] - Investors can access the conference call by dialing +1 (800) 715-9871 for U.S. and Canada or +1 (646) 307-1963 for international calls, using conference ID 2270373 [1] Product Information - Avadel's commercial product, LUMRYZ™, is the first and only once-at-bedtime oxybate approved by the FDA for treating cataplexy or excessive daytime sleepiness in adults with narcolepsy [2]